tiprankstipranks
Trending News
More News >

Goldman Sachs Increases Stake in Mayne Pharma Group

Story Highlights
Goldman Sachs Increases Stake in Mayne Pharma Group

Confident Investing Starts Here:

The latest update is out from Mayne Pharma Group ( (AU:MYX) ).

Goldman Sachs Group, Inc. has increased its voting power in Mayne Pharma Group Limited from 7.54% to 8.55% by acquiring additional fully paid ordinary shares. This change in substantial holding indicates a growing interest and investment by Goldman Sachs in Mayne Pharma, potentially impacting the company’s market positioning and signaling confidence in its future prospects.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of oral and topical products, serving markets in Australia and internationally.

Average Trading Volume: 910,549

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$400.5M

For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App